Your browser doesn't support javascript.
loading
Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia".
Perrotti, Danilo; Agarwal, Anupriya; Lucas, Claire M; Narla, Goutham; Neviani, Paolo; Odero, Maria D; Ruvolo, Peter P; Verrills, Nicole M.
Affiliation
  • Perrotti D; University of Maryland School of Medicine, Baltimore, MD 21201, USA. dperrotti@som.umaryland.edu.
  • Agarwal A; Department of Haematology, Imperial College London, London W12 0HS, UK.
  • Lucas CM; Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA.
  • Narla G; University of Chester Medical School, Chester CH2 1BR, UK.
  • Neviani P; Department of Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
  • Odero MD; Keck School of Medicine, University of Southern California, Los Angeles, CA 90027, USA.
  • Ruvolo PP; University of Navarra, Pamplona 31009, Spain.
  • Verrills NM; Department of Leukemia, MD Anderson Cancer Center, Houston, 77054 TX, USA.
Sci Transl Med ; 11(501)2019 07 17.
Article in En | MEDLINE | ID: mdl-31316003
ABSTRACT
LB100 does not sensitize CML stem cells to tyrosine kinase inhibitor-induced apoptosis.
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myelogenous, Chronic, BCR-ABL Positive Limits: Humans Language: En Journal: Sci Transl Med Journal subject: CIENCIA / MEDICINA Year: 2019 Document type: Article Affiliation country: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myelogenous, Chronic, BCR-ABL Positive Limits: Humans Language: En Journal: Sci Transl Med Journal subject: CIENCIA / MEDICINA Year: 2019 Document type: Article Affiliation country: United States